In 2026, users of the Wiener Linien can expect a comprehensive modernization of the public transport network with the renewal of over 12 kilometers of tram tracks, the extension of line 18, and the in ...

Summary • Vor Biopharma Inc. (VOR) shares increased by 10.9% to $15.01 following new board appointments.• The company announced a $150 million PIPE financing, enhancing growth and strategic leadership ...

Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of ...

Vor Biopharma has done well to continue to advance its very own global phase 3 study using its dual BAFF/APRIL inhibitor ...

Vor Bio intends to use the net proceeds from the private placement to advance the clinical development of telitacicept, including the ongoing global Phase 3 clinical trial for myasthenia gravis and ...

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

Investing.com - JPMorgan initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a $43.00 price target, citing the potential of its telitacicept drug. The target ...

Vor Biopharma Inc. (VOR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

Many pilots will recognise my situation. About 230 hours in my logbook plus a bit of time learning to glide, but I had started learning in 1977, 38 years before. Then I bought an old ? but lovely ?

German war-themed metal act Kanonenfieber have dropped their new single "Z-Vor!"" just in time for their early-hours set at Summer Breeze Open Air on Thursday night into Friday morning. The track ...

US clinical-stage biotech Vor Bio (Nasdaq: VOR) has announced the appointment of Dallan Murray as chief commercial officer, effective immediately. “We’re thrilled to welcome Dallan to Vor Bio at this ...

Vor Bio has handed Dallan Murray a swift return to the workforce. Weeks after being let go by Sarepta Therapeutics, Murray has landed the chief commercial officer post in Vor’s new-look C-suite.